Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Cellular Biomedicine Group to Present Cancer CAR-T CD30 Therapy Clinical Development Program


Cellular Biomedicine Group Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that management will present the Company's Chimeric Antigen Receptor T cell (CAR-T) therapy for cancer clinical development programs at the previously announced 10th Annual World Stem Cells & Regenerative Medicine Congress to be held at the Business Design Centre in London, UK on May 20-22, 2015.

Dr. William (Wei) Cao, Chief Executive Officer, will speak on May 21, 2015 at 2:50pm during the segment titled "Spotlight On T-Cells". He will present Phase I clinical data from the Company's CAR-T programs, specifically the recombinant expression vector CD30 for Hodgkin's lymphoma. More information about the Congress and registration information can be found here.

Posted-In: News FDA Press Releases


Related Articles (CBMG)

View Comments and Join the Discussion!

JP Morgan Previews Apple's Q2, Expects 'Negligible' FX Impact & Strong iPhone Sales

Cabot Oil & Gas A 'Top Pick' For Barclays